Impact of pasireotide on bone health in acromegaly
Part of Bones, joints & muscles, Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This trial studies how pasireotide LAR—a drug that controls growth hormone levels—affects bone health in people with acromegaly whose disease is not well-controlled after 6 months of another therapy. It may help patients understand the bone benefits of switching to this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acromegaly that is not fully controlled after at least 6 months of treatment with a first-generation somatostatin receptor ligand (such as octreotide or lanreotide).
- You have been switched to pasireotide LAR at least 1 week ago (prospective group), or you were switched to pegvisomant previously (retrospective group).
- You are willing to sign a consent form (or have a substitute decision-maker do so).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how treatments for acromegaly affect how you function and move, especially in your hands, feet, and overall body structure. You may be asked to do assessments to understand changes over time and whether certain groups respond differently.
This trial tests if switching from a standard somatostatin analog to pasireotide can better control acromegaly in patients whose growth hormone and IGF-1 levels remain high. It aims to offer a more effective treatment option for those not responding well enough to initial therapy.
This study follows people with acromegaly to better understand how treatments are used in real life and how well they work over time. It may help improve future treatment choices by comparing outcomes across different care patterns.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
This trial tests if a ketogenic (very low-carb) diet can help lower IGF-I levels in people with acromegaly who are already on stable medication. If you have acromegaly and your IGF-I levels are still above normal despite treatment, this diet might offer an additional way to manage your condition.
Hear when a new Acromegaly Due to Pituitary Adenoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.